Vaccination against pandemic influenza A/H1N1v in England: A real-time economic evaluation


Baguelin, M; van Hoek, AJ; Jit, M; Flasche, S; White, PJ; Edmunds, WJ; (2010) Vaccination against pandemic influenza A/H1N1v in England: A real-time economic evaluation. Vaccine, 28 (12). pp. 2370-2384. ISSN 0264-410X DOI: 10.1016/j.vaccine.2010.01.002

Full text not available from this repository. (Request a copy)

Abstract

Decisions on how to mitigate an evolving pandemic are technically challenging. We present a real-time assessment of the effectiveness and cost-effectiveness of alternative influenza A/H1N1v vaccination strategies. A transmission dynamic model was fitted to the estimated number of cases in real-time, and used to generate plausible autumn scenarios under different vaccination options. The proportion of these cases by age and risk group leading to primary care consultations, National Pandemic Flu Service consultations, emergency attendances, hospitalisations, intensive care and death was then estimated using existing data from the pandemic. The real-time model suggests that the epidemic will peak in early November, with the peak height being similar in magnitude to the summer wave. Vaccination of the high-risk groups is estimated to prevent about 45 deaths (80% credibility interval 26-67), and save around 2900 QALYs (80% credibility interval 1600-4500). Such a programme is very likely to be cost-effective if the cost of vaccine purchase itself is treated as a sunk cost. Extending vaccination to low-risk individuals is expected to result in more modest gains in deaths and QALYs averted. Extending vaccination to school-age children would be the most cost-effective extension. The early availability of vaccines is crucial in determining the impact of such extensions. There have been a considerable number of cases of H1N1v in England, and so the benefits of vaccination to mitigate the ongoing autumn wave are limited. However, certain groups appear to be at significantly higher risk of complications and deaths, and so it appears both effective and cost-effective to vaccinate them. The United Kingdom was the first country to have a major epidemic in Europe. In countries where the epidemic is not so far advanced vaccination of children may be cost-effective. Similar, detailed, real-time modelling and economic studies could help to clarify the situation. (C) 2010 Elsevier Ltd. All rights reserved.

Item Type: Article
Keywords: Influenza, Vaccination, Mathematical Model, cost-effectiveness, disease, wales
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology
Research Centre: Vaccine Centre
PubMed ID: 20096762
Web of Science ID: 276135200004
URI: http://researchonline.lshtm.ac.uk/id/eprint/3853

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
323Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item